Medullary thyroid carcinoma: biology, management, and treatment of sporadic and hereditary MTC

What is new? -- Thyroid C-Cell Biology and Oncogenic Transformation -- Histopathology of C cells and medullary thyroid carcinoma -- Epidemiology and clinical presentation of Medullary Thyroid Carcinoma -- Medullary thyroid carcinoma: Imaging -- Calcitonin as a Biomarker for Medullary Thyroid Carcino...

Full description

Saved in:
Bibliographic Details
Other Authors: Raue, Friedhelm (Editor) , Frank-Raue, Karin (Editor)
Format: Book/Monograph
Language:English
Published: Cham Springer Nature Switzerland 2025.
Cham Imprint: Springer 2025.
Edition:2nd ed. 2025.
Series:Recent Results in Cancer Research 223
DOI:10.1007/978-3-031-80396-3
Online Access:Resolving-System, lizenzpflichtig: https://doi.org/10.1007/978-3-031-80396-3
Get full text
Author Notes:edited by Friedhelm Raue, Karin Frank-Raue
Description
Summary:What is new? -- Thyroid C-Cell Biology and Oncogenic Transformation -- Histopathology of C cells and medullary thyroid carcinoma -- Epidemiology and clinical presentation of Medullary Thyroid Carcinoma -- Medullary thyroid carcinoma: Imaging -- Calcitonin as a Biomarker for Medullary Thyroid Carcinoma -- Hereditary Medullary Thyroid Cancer, Genotype phenotype correlation -- Pheochromocytomas in Multiple Endocrine Neoplasia type 2 -- Primary hyperparathyroidism in Multiple Endocrine Neoplasia 2 Syndrome -- Surgical treatment of medullary thyroid carcinoma -- Long term follow up in medullary thyroid carcinoma -- Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists. Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC. This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.
Physical Description:Online Resource
ISBN:9783031803963
DOI:10.1007/978-3-031-80396-3